Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Intravenous HRS8179 for the Prevention and Treatment of Severe Cerebral Edema Following Large Hemispheric Infarction: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II/III Clinical Trial

NCT06732648 is registered in ClinicalTrials.gov with Beijing Suncadia Pharmaceuticals Co., Ltd as lead sponsor.

NCT NCT06732648
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06732648 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Intravenous HRS8179 for the Prevention and Treatment of Severe Cerebral Edema Following Large Hemispheric Infarction: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II/III Clinical Trial
Lead sponsor
Beijing Suncadia Pharmaceuticals Co., Ltd
Phase
Phase 2/3
Overall status
Recruiting
Start date
February 7, 2025
Completion date
September 30, 2027
Enrollment
725 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

severe cerebral edema following large hemispheric infarction